Multiple myeloma trials in Poland

In Poland 39 Also abroad 704

39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Gdansk, Katowice, Lodz, Lublin
Age
18 years and over
People
410 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00
Phase 1/2Taking people
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Where
Gdansk, Olsztyn, Poznan, Warsaw
Age
18 years and over
People
200 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05583617 · EU 2023-504484-16-00
Phase 3Taking people
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Gdansk, Katowice, Lodz, Lublin, Walbrzych, Warsaw, Wroclaw
Age
18 years and over
People
915 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00
Phase 3Taking people
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Where
Cracow, Gdansk, Katowice, Kielce, Lodz, Skorzewo, Warsaw
Age
18 years and over
People
270 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00
Phase 2Not yet taking people in Poland
A Randomized, Double-Blind, Phase 2 Trial Evaluating the Efficacy, Safety and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
Where
Brzozów, Gdansk, Gliwice, Katowice, Krakow, Lublin, Olsztyn, Rzeszów, Slupsk, Szczecin, Torun, Warsaw, Wroclaw
Age
18 years and over
People
418
Run by
Instytut Hematologii I Transfuzjologii
See details and how to join2026-525418-67-00 · EU 2026-525418-67-00
Phase 2Taking people
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Gdansk, Poznan, Warsaw, Wroclaw
Age
18 years and over
People
510 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Brzozów, Bydgoszcz, Katowice, Kielce, Lodz, Lublin, Poznan, Warsaw
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 3Taking people
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Where
Bydgoszcz, Chorzów, Gdansk, Katowice, Kielce, Krakow, Lublin, Szczecin, Wroclaw
Age
18 years and over
People
1,000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07665450
Phase 3Taking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Katowice, Krakow, Skórzewo, Słupsk, Torun, Warsaw
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 2Taking people
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Where
Bydgoszcz, Gdansk, Katowice, Wroclaw
Age
18 years and over
People
100 worldwide
Run by
C4 Therapeutics, Inc.
See details and how to joinNCT07284758 · EU 2025-524181-26-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Gdansk, Lodz, Lublin
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Gdansk, Katowice, Wroclaw
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Lublin, Poznan, Warsaw
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00
Phase 3Taking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Gdansk, Gliwice, Kielce, Krakow, Lublin, Wroclaw
Age
18 years to 130 years
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637
Phase 1Taking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Gdansk, Katowice, Poznan
Age
18 years and over
People
186 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00
Phase 3Taking people
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
Where
Bydgoszcz, Gdansk, Katowice, Lublin, Walbrzych, Warsaw
Age
18 years and over
People
206 worldwide
Run by
Janssen Cilag International
See details and how to join2025-523815-12-00 · EU 2025-523815-12-00
Phase 3Taking people
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Where
Bydgoszcz, Chorzów, Cracow, Gdansk, Katowice, Kielce, Lodz, Lublin, Poznan, Szczecin, Wroclaw
Age
18 years and over
People
423 worldwide
Run by
Janssen Cilag International
See details and how to join2026-526654-14-01 · EU 2026-526654-14-01
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Gliwice, Katowice, Krakow, Skorzewo (Poznan), Torun
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
Phase 3Taking people
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Where
Cracow, Gdansk, Katowice, Kielce, Skorzewo
Age
18 years and over
People
183 worldwide
Run by
Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00
Phase 3Taking people
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
Cracow, Gdansk, Poznan, Szczecin, Warsaw, Wroclaw
Age
18 years and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
Phase 3Not yet taking people in Poland
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
Where
Cracow, Gdansk, Gliwice, Kielce, Lublin, Wroclaw
Age
18 years and over
People
249 worldwide
Run by
AstraZeneca AB
See details and how to join2026-525367-40-00 · EU 2026-525367-40-00
Phase 3Taking people
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Where
Gdansk, Poznan
Age
18 years and over
People
1,594 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT05243797 · EU 2023-510384-36-00
Phase 3Taking people
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Where
Katowice, Kielce, Krakow, Lublin, Skorzewo
Age
18 years and over
People
49 worldwide
Run by
Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00
Phase 3Taking people
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Where
Bydgoszcz, Cracow, Legnica, Olsztyn, Slupsk, Torun, Walbrzych
Age
18 years and over
People
386 worldwide
Run by
Grifols Therapeutics LLC
See details and how to joinNCT05645107 · EU 2022-502193-16-00
Phase 3Taking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Gdansk, Gliwice, Lublin, Poznan, Warsaw, Wroclaw
Age
18 years and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657